61270-58-4 Usage
Description
Cefonicid is a semi-synthetic cephalosporin antibiotic related to Cefamandole, characterized by an unesterified D-mandelic acid moiety at C-7 and a methylsulfothiotetrazole group at C-3. It is known for its longer half-life compared to other members of its group, although it may have somewhat lower potency against Gram-positive bacteria and aerobes. Cefonicid is sold as an injectable disodium salt and is used for its antibacterial properties.
Uses
Used in Pharmaceutical Industry:
Cefonicid is used as an antibiotic for treating bacterial infections. Its application is due to its ability to target and eliminate a wide range of bacteria, making it a valuable tool in the treatment of various infections.
Used in Medical Treatments:
Cefonicid is used as a therapeutic agent for combating bacterial infections, particularly those caused by Gram-negative and some Gram-positive bacteria. Its application is attributed to its effectiveness in treating infections and its longer half-life, which may reduce the frequency of administration.
Antimicrobial activity
Activity against Gram-positive and Gram-negative organisms
in vitro is depressed by the presence of 50% serum. It is highly
bound to plasma protein (98%) and has an extended plasma
half-life of 4.5–5 h. A 1 g intramuscular dose achieves a mean
peak plasma concentration of around 83 mg/L. Following a
1 g intravenous bolus dose, mean peak plasma concentrations
of 130–300 mg/L have been reported. In patients treated for
community-acquired pneumonia, concentrations of 2–4 mg/L
have been found in sputum.
It is predominantly excreted by renal secretion, 83–89%
being recovered unchanged in the urine over 24 h. Plasma
half-life is linearly related to creatinine clearance. As a
result of its high protein binding it is not removed by
hemodialysis.
It is generally well tolerated; pain on injection, rash and
positive Coombs’ test are reported in some patients. It has
been used to treat respiratory, soft tissue and urinary infections.
Available in Italy.
Synthesis
Cefonicid, 7-D-mandelamido-3-[[(1-sulfomethyl]-1H-tetrazol-5-yl]thio] methyl]-
8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.26), is structurally similar
to cefamandole and differs in the presence of a sulfonic acid group in the methyl substituent
of the tetrazol ring. It is synthesized by a method analogous to that of the synthesis of
cefamandole.
Check Digit Verification of cas no
The CAS Registry Mumber 61270-58-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,2,7 and 0 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 61270-58:
(7*6)+(6*1)+(5*2)+(4*7)+(3*0)+(2*5)+(1*8)=104
104 % 10 = 4
So 61270-58-4 is a valid CAS Registry Number.
InChI:InChI=1/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
61270-58-4Relevant articles and documents
Coupling of Site-Directed mutagenesis and immobilization for the rational design of more efficient biocatalysts: The case of immobilized 3G3K PGA from E. coli
Serra, Immacolata,Ceechini, Davide A.,UbiaIi, Daniela,Manazza, Elena M.,Albertini, Alessandra M.,Terreni, Marco
experimental part, p. 1384 - 1389 (2009/08/07)
We have investigated the synthetic performance of the immobilized 3G3K mutant of the Penicillin G acylase (PGA) from E. coli obtained by site-directed mutagenesis. The 3G3K mutant, characterized by a tag consisting of three lysines alternating with three